SLV308 -: Antiparkinsonian -: Antidepressant -: Anxiolytic -: Dopamine D2 partial agonist -: 5-HT1A agonist

被引：9
作者：
Feenstra, R [1 ]
Ronken, E [1 ]
Koopman, T [1 ]
de Vries, M [1 ]
McCreary, A [1 ]
Stoker, M [1 ]
van Charldorp, K [1 ]
Long, S [1 ]
van Scharrenburg, G [1 ]
机构：
[1] Solvay Pharmaceut, NL-1380 DA Weesp, Netherlands
来源：
DRUGS OF THE FUTURE | 2001年 / 26卷 / 02期
关键词：
D O I：
10.1358/dof.2001.026.02.608830
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：128 / 132
页数：5
相关论文
共 50 条
  • [41] N-0923 -: SPM-962 -: Antiparkinsonian -: Dopamine D2 agonist
    不详
    DRUGS OF THE FUTURE, 2000, 25 (11) : 1214 - 1215
  • [42] PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions.: II.: Preclinical behavioral effects
    Corbin, AE
    Meltzer, LT
    Ninteman, FW
    Wiley, JN
    Cristoffersen, CL
    Wustrow, DJ
    Wise, LD
    Pugsley, TA
    Heffner, TG
    NEUROPHARMACOLOGY, 2000, 39 (07) : 1211 - 1221
  • [43] Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors?
    Jackson, DM
    Wikström, H
    Liao, Y
    PSYCHOPHARMACOLOGY, 1998, 138 (02) : 213 - 214
  • [44] SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile
    Yves Claustre
    Danielle De Peretti
    Philippe Brun
    Christiane Gueudet
    Nathalie Allouard
    Richard Alonso
    Joëlle Lourdelet
    André Oblin
    Gabrielle Damoiseau
    Dominique Françon
    Marie-Françoise Suaud-Chagny
    Régis Steinberg
    Mireille Sevrin
    Hans Schoemaker
    Pascal George
    Philippe Soubrié
    Bernard Scatton
    Neuropsychopharmacology, 2003, 28 : 2064 - 2076
  • [45] SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist.: I:: Neurochemical and electrophysiological profile
    Claustre, Y
    De Peretti, D
    Brun, P
    Gueudet, C
    Allouard, N
    Alonso, R
    Lourdelet, J
    Oblin, A
    Damoiseau, G
    Françon, D
    Suaud-Chagny, MF
    Steinberg, R
    Sevrin, M
    Schoemaker, H
    George, P
    Soubrié, P
    Scatton, B
    NEUROPSYCHOPHARMACOLOGY, 2003, 28 (12) : 2064 - 2076
  • [46] On the elevated plus-maze the anxiolytic-like effects of the 5-HT1A agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT1A partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635
    N. Collinson
    G. R. Dawson
    Psychopharmacology, 1997, 132 : 35 - 43
  • [47] SSR181507, a dopamine D2 receptor and 5-HT1A receptor ligand: Evidence for mixed anxiolytic- and antidepressant-like activities
    Boulay, Denis
    Depoortere, Ronan
    Louis, Caroline
    Lacave, Martine
    Lucas, Marie Therese
    Griebel, Guy
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 97 (03) : 428 - 435
  • [48] Additive hypothermic effects of the 5-HT1A receptor agonist 8-OH-DPAT and the dopamine D2/3 receptor agonist 7-OH-DPAT in the rat
    Eltayb, A
    Lindblom, S
    Oerther, S
    Ahlenius, S
    ACTA PHYSIOLOGICA SCANDINAVICA, 2001, 172 (03): : 205 - 209
  • [49] A 5-HT1A LIGAND WITH BOTH ANTIDEPRESSANT AND ANXIOLYTIC PROPERTIES
    COTT, JM
    KURTZ, NM
    ROBINSON, DS
    LANCASTER, SP
    COPP, JE
    PSYCHOPHARMACOLOGY BULLETIN, 1988, 24 (01) : 164 - 167
  • [50] The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
    Jordan, S
    Koprivica, V
    Chen, RY
    Tottori, K
    Kikuchi, T
    Altar, CA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 441 (03) : 137 - 140
12345